Takeda Vaccines, Inc.

Ribozyme Pharmaceuticals, Incorporated

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Other

Heska Corporation

Igm Biosciences, Inc.

Warner-lambert Company

Chiron Corporation

Sirna Therapeutics, Inc.

Warner Lambert LLC

Inviragen, Inc.

Dan T Stinchcomb

James A McSwiggen

Jorge E Osorio

Kenneth G Draper

Jill Ann Livengood

Joseph N Brewoo

Richard M Kinney

Claire Kinney

Timothy D Powell

Thale Jarvis

Sean M Sullivan

Charalambos D Partidos

O'Neil Wiggan

Pamela Pavco

Nancy Wisnewski

James D Thompson

Ramani S Wonderling

Bharat Chowrira

Susan Grimm

Subash Chandra Das

Joseph David Santangelo

Joel R Haynes

Richard M Soll

Sanath K Meegalla

Bruce Alan Keyt

Ole Olsen

Jaime A Escobedo

Daljit Singh Dhanoa

Dimitris K Agrafiotis

Gary M Silver

Roger Schofield Newton

Randy Ranjee Ramharack

Jeremy C Jones

Dario Doller

Laszlo Varga

R Lee Seward

John Gustofson

Kevin S Brandt

Charles Larry Bisgaier

Patrick J Gaines

Deyou Sha

Claire Y Huang

Kevin Kisich

Larry Couture

Michael Pape

Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.

Compositions and methods for dengue virus chimeric constructions in vaccines

Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.

Methods and compositions for live attenuated viruses

This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof

Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.

Compositions, methods and uses for dengue virus serotype-4 constructs

Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.

Compositions and methods for live, attenuated alphavirus formulations

The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.

Hand, foot, and mouth vaccines and methods of manufacture and use thereof

Compositions and methods for dengue virus chimeric constructs in vaccines

Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.

Compositions and methods for administration of vaccines against dengue virus

Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally relate to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.

Compositions, methods and uses for inducing viral growth

Growing community of inventors

Boulder, CO, United States of America

Dan T Stinchcomb